$7.55
-0.085-1.11%
Last update: Nov 9, 5:25 PM
AgomAb Therapeutics NV
AGMBNASDAQ
The average analyst price target for AgomAb Therapeutics is $37.50, 403.4% above the current price. Of 7 analysts, 7 rate it Buy. Targets range from $28 to $60. The latest change came on Aug 25, 2026, when Piper Sandler initiated coverage of AgomAb Therapeutics with an Overweight rating and a $60 price target.
Price Target Range — 3 Quarters
Analyst Consensus — 7 Analysts
Rating Trend — Last 9 Months
